Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-α-refractory adult T-cell leukemia

Blood

Volumn 106, Issue 10, 2005, Pages 3380-3382

  Mone, Andrew ^b   Puhalla, Shannon ^b   Whitman, Susan ^b   Baiocchi, Robert A ^b   Cruz, Julio ^b   Vukosavljevic, Tamara ^b   Banks, Amy ^b   Eisenbeis, Charles F ^b   Byrd, John C ^b   Caligiuri, Michael A ^b   Porcu, Pierluigi ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; LAMIVUDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STAVUDINE; THALIDOMIDE; VALGANCICLOVIR; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD EXAMINATION; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC LEUKEMIA; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DISEASE COURSE; DRUG EFFICACY; DRUG INDICATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; LABORATORY TEST; LYMPHOCYTOSIS; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; SKIN DEFECT; T CELL LEUKEMIA; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD;

EID: 27744590996     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-01-0335     Document Type: Article

References (25)

1. Maloney EM, Blattner WA. HTLV-1 worldwide patterns and disease associations. In: Sugamura K, Uchiyama T, Matsuoka M, and Kannagi M, eds. Gann Monographs on Cancer Research. Vol 50. Japan Science Societies Press; 2003:339-361.
2. Ratner L. Adult T cell leukemia lymphoma. Front Biosci. 2004;9:2852-2859.
3. Yamada Y, Tomonaga M. The current status of therapy for adult T-cell leukaemia-lymphoma in Japan. Leuk Lymphoma. 2003;44:611-618.
4. Hatta Y, Koeffler HP. Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL). Leukemia. 2002;16:1069-1085.
5. Sun SC, Ballard DW. Persistent activation of NF-kappaB by the tax transforming protein of HTLV-1: hijacking cellular IkappaB kinases. Oncogene. 1999;18:6948-6958.
6. Kamihira S, Dateki N, Sugahara K, et al. Significance of HTLV-1 proviral load quantification by real-time PCR as a surrogate marker for HTLV-1-infected cell count. Clin Lab Haematol. 2003;25:111-117.
7. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy. 2001;3:137-143.
8. Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 2003;63:6453-6457.
9. Miley WJ, Suryanarayana K, Manns A, et al. Real-time polymerase chain reaction assay for cell-associated HTLV type I DNA viral load. AIDS Res Hum Retroviruses. 2000;16:665-675.
10. Hale G, Clark M, Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol. 1985;134:3056-3061.
11. Mone AP, Huang P, Pelicano H, et al. Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood. 2004;103:1846-1854.
12. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278-3281.
13. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721-1726.
14. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101:4267-4272.
15. Dearden C. Alemtuzumab in peripheral T-cell malignancies. Cancer Biother Radiopharm. 2004;19:391-398.
16. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med. 2002;347:452-453.
17. Abe Y, Yashiki S, Choi I, et al. Eradication of virus-infected T-cells in a case of adult T-cell leukemia/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin. Int J Hematol. 2002;76:91-93.
18. Tajima K, Amakawa R, Uehira K, et al. Adult T-cell leukemia successfully treated with allogeneic bone marrow transplantation. Int J Hematol. 2000;71:290-293.
19. Hishizawa M, Imada K, Ishikawa T, Uchiyama T. Kinetics of proviral DNA load, soluble interleukin-2 receptor level and tax expression in patients with adult T-cell leukemia receiving allogeneic stem cell transplantation. Leukemia. 2004;18:167-169.
20. Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol. 2002;19(suppl):S27-S32.
21. Morris JC, O'Mahony D, Lee CC, et al. A phase II study of the efficacy and toxicity of Campath-1H (anti-CD52) for the therapy of adult T-cell leukemia (ATL): early results. AIDS Res Hum Retroviruses. 2005;21:446. Abstract 022.
22. Lin TS, Flinn IW, Modali R, et al. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood. 2005;105:289-291.
23. Harashima N, Kurihara K, Utsunomiya A, et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res. 2004;64:391-399.
24. Mortreux F, Gabet AS, Wattel E. Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia. 2003;17:26-38.
25. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768-773.